Needham analyst Alan Carr maintained a Hold rating on Neurocrine (NBIX) today. The company’s shares closed last Monday at $103.10.
According to TipRanks.com, Carr is ranked 0 out of 5 stars with an average return of -1.9% and a 40.8% success rate. Carr covers the Healthcare sector, focusing on stocks such as Lexicon Pharmaceuticals, Phathom Pharmaceuticals, and ACADIA Pharmaceuticals.
Neurocrine has an analyst consensus of Strong Buy, with a price target consensus of $126.10.
See today’s analyst top recommended stocks >>
Neurocrine’s market cap is currently $9.49B and has a P/E ratio of 610.42. The company has a Price to Book ratio of 16.52.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neurocrine Biosciences, Inc. operates as a product based bio-pharmaceutical company. It discovers, develops and intends to commercialize drugs for the treatment of neurological and endocrine related diseases and disorders.